Analiz Rodriguez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8820968/publications.pdf

Version: 2024-02-01

933447 677142 40 522 10 22 citations g-index h-index papers 41 41 41 1034 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Dr. Louise Eisenhardt's personal notes: how she and Dr. Cushing collected data and followed patients. Journal of Neurosurgery, 2022, 136, 1173-1178.	1.6	O
2	323 Generation of a functional precision medicine pipeline which combines comparative transcriptomics and tumor organoid modeling to identify bespoke treatment strategies for glioblastoma. Journal of Clinical and Translational Science, 2022, 6, 58-58.	0.6	0
3	Monensin and its analogues show antiâ€glioblastoma activity in an organoid model of cancer. FASEB Journal, 2022, 36, .	0.5	O
4	An Examination of Patients and Caregivers on Reddit Navigating Brain Cancer: Content Analysis of the Brain Tumor Subreddit. JMIR Cancer, 2022, 8, e35324.	2.4	3
5	Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis Journal of Clinical Oncology, 2022, 40, 2031-2031.	1.6	O
6	The Original Cushing Society: A Historical Review of the Senior Society's First 6 Meetings. World Neurosurgery, 2021, 147, 130-143.	1.3	0
7	Racial and ethnic disparities among children with primary central nervous system tumors in the US. Journal of Neuro-Oncology, 2021, 152, 451-466.	2.9	4
8	Brain Tumor Biobank Development for Precision Medicine: Role of the Neurosurgeon. Frontiers in Oncology, 2021, 11, 662260.	2.8	10
9	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery, 2021, 89, 129-132.	1.1	5
10	DNA Polymerase Kappa Acts as a Barrier to Unrestrained Replication in Glioblastoma. FASEB Journal, 2021, 35, .	0.5	0
11	Pulsed reduced dose-rate radiotherapy for previously irradiated tumors in the brain and spine. , 2021, 12, 280.		2
12	Recent trends in NIH funding for top surgeon-scientists. American Journal of Surgery, 2021, 222, 281-285.	1.8	6
13	The Presence and Potential Role of ALDH1A2 in the Glioblastoma Microenvironment. Cells, 2021, 10, 2485.	4.1	6
14	Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion. International Journal of Molecular Sciences, 2021, 22, 10720.	4.1	11
15	Primary glioblastoma of the cauda equina with molecular and histopathological characterization: case report. Neuro-Oncology Advances, 2021, 3, vdab154.	0.7	O
16	Transsulcal parafascicular brain path-assisted approach to subcortical lesions: 2-dimensional operative video. Surgical Neurology International, 2021, 12, 107.	0.2	1
17	Genomic and Transcriptomic Profiling of Brain Metastases. Cancers, 2021, 13, 5598.	3.7	O
18	QOLP-26. ANALYSIS OF REDDIT USERS' PERSPECTIVES OF BRAIN TUMORS. Neuro-Oncology, 2021, 23, vi188-vi188.	1.2	0

#	Article	IF	Citations
19	A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. Cells, 2021, 10, 3400.	4.1	15
20	Misogynoir. Journal of Graduate Medical Education, 2021, 13, 795-796.	1.3	0
21	3D cultures for modeling nanomaterial-based photothermal therapy. Nanoscale Horizons, 2020, 5, 400-430.	8.0	34
22	Pituitary Metastatic Composite Tumors: A Case Report with Next-Generation Sequencing and Review of the Literature. Case Reports in Oncological Medicine, 2020, 2020, 1-8.	0.3	2
23	Association of Insurance Status With Treatment and Outcomes in Pediatric Patients With Severe Traumatic Brain Injury. Critical Care Medicine, 2020, 48, e584-e591.	0.9	7
24	Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression. Acta Neuropathologica Communications, 2020, 8, 157.	5.2	5
25	CAR T Cell Therapy for Pediatric Brain Tumors. Frontiers in Oncology, 2020, 10, 1582.	2.8	37
26	Surgical Treatment of Symptomatic Small Medial Petrous Meningiomas Causing Trigeminal Neuralgia. World Neurosurgery, 2020, 139, e761-e768.	1.3	1
27	A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma. Acta Neuropathologica Communications, 2020, 8, 87.	5.2	24
28	LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). Neuro-Oncology, 2020, 22, ii237-ii237.	1.2	21
29	A Glioblastoma Genomics Primer for Clinicians. Medical Research Archives, 2020, 8, .	0.2	10
30	Neurosurgical management of perineural metastases: A case series and review of the literature. , 2020, 11, 206.		0
31	EPCO-23. COMPARATIVE TRANSCRIPTOMICS TO IDENTIFY TARGETED THERAPY CANDIDATES IN HIGH GRADE GLIOMA. Neuro-Oncology, 2020, 22, ii74-ii74.	1.2	0
32	SMARC-B1 deficient sinonasal carcinoma metastasis to the brain with next generation sequencing data: a case report of perineural invasion progressing to leptomeningeal invasion. BMC Cancer, 2019, 19, 827.	2.6	9
33	GENE-18. TRANSCRIPTOME-WIDE ANALYSIS USING NANOPORE THIRD GENERATION SEQUENCING IN A RAT GLIOBLASTOMA MODEL: PROOF OF PRINCIPLE. Neuro-Oncology, 2019, 21, vi101-vi101.	1.2	0
34	PATH-05. RAPID SIMULTANEOUS IDH MUTATION AND MGMT METHYLATION STATUS ASSESSMENT IN GLIOMA PATIENTS USING CRISPR-Cas9-TARGETED NANOPORE SEQUENCING. Neuro-Oncology, 2019, 21, vi143-vi144.	1.2	0
35	Effects of thioTEPA chemotherapy on cognition and motor coordination. Synapse, 2019, 73, e22085.	1.2	6
36	Long-Term Changes in Cognition and Physiology after Low-Dose 160 Irradiation. International Journal of Molecular Sciences, 2019, 20, 188.	4.1	26

3

#	Article	IF	CITATIONS
37	Chimeric antigen receptor T-cell therapy for glioblastoma. Translational Research, 2017, 187, 93-102.	5.0	27
38	Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Frontiers in Immunology, 2017, 8, 1850.	4.8	161
39	Neurosurgical Techniques for Disruption of the Blood–Brain Barrier for Glioblastoma Treatment. Pharmaceutics, 2015, 7, 175-187.	4.5	86
40	Diversity within the Neurosurgical Oncology Workforce in the United States: A Cross-Sectional Study with Proposed Strategies to Pave the Path Forward. Neuro-Oncology, 0, , .	1.2	0